Stock-based compensation (Tables)

3 Months Ended

Mar. 31, 2021

Share-based Payment Arrangement [Abstract]

Schedule of Stock Option Activity

Stock option activity under the 2015 Plan for the three months ended March 31, 2021 is as follows:

	Number of Shares Available for Grant	Number of Shares Underlying Outstanding Options	Weighted- Average Exercise Price per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding—December 31, 2020	1,587,195	25,732,503	$	0.39	9.6	$	245,746
Shares repurchased	220,561	—	0.14			$	—
Options exercised	—	(727,114)	0.13		9.0	$	6,083
Options cancelled	378,639	(378,641)	0.15			$	—
Outstanding—March 31, 2021	2,186,395	24,626,748	$	0.41	9.4	$	199,328
Vested and expected to vest—March 31, 2021		24,626,748	$	0.41	9.4	$	199,328
Exercisable—March 31, 2021		5,969,870	$	0.26	9.2	$	49,206

Schedule of Stock Options Outstanding and Exercisable

The following table summarizes information about stock options outstanding and exercisable at March 31, 2021 under the 2015 Plan.

		Options Outstanding				Options Exercisable
Exercise Price		Options Outstanding	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price		Options Exercisable	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price
$	0.13	6,583,852	9.16	$	0.13	3,235,053	9.16	$	0.13
$	0.15	10,474,328	9.46	$	0.15	1,906,603	9.28	$	0.15
$	0.26	35,159	0.2	$	0.26	35,159	0.2	$	0.26
$	1.00	7,524,115	9.5	$	1.00	783,761	9.5	$	1.00
$	3.92	7,976	0.2	$	3.92	7,976	0.2	$	3.92
$	5.80	1,318	0.2	$	5.80	1,318	0.2	$	5.80
		24,626,748				5,969,870

Schedule of Nonvested Restricted Stock Awards Activity

A summary of RSAs activity under the 2015 Plan is as follows:

	Number of Shares	Weighted Average Grant Date Fair Value (per share)
Unvested – December 31, 2020	57,956	$	0.67
Granted during the period	—	—
Canceled during the period	—	—
Vested during the period	(8,279)	0.67
Unvested — March 31, 2021	49,677	$	0.67

Schedule of Stock-based Compensation

The Company recognized stock-based compensation for all stock options in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):

	Three Months Ended March 31,
	2021		2020
Cost of revenue	$	118	$	42
Research and development	921		136
Sales and marketing	265		50
General and administrative	3,952		(53)
Total stock-based compensation	$	5,256	$	175